Hereditary cancer predisposition associated with ATM is a tumor susceptibility syndrome of moderate penetrance caused by heterozygous pathogenic germline variants in ATM. It is inherited in an autosomal dominant manner and primarily increases the risk of female breast, pancreatic, and prostate cancer. Decreased ATM activity alters the response to DNA double-strand breaks and favors genomic instability and tumor transformation.
Hereditary cancer (ATM gene)
ATM encodes a serine/threonine kinase that regulates the cellular response to DNA damage. Following a double-strand break, ATM is activated and phosphorylates proteins such as p53, CHK2, BRCA1, and H2AX, coordinating cell cycle arrest, DNA repair, or apoptosis. This system prevents damaged cells from accumulating and transmitting genomic alterations.
Pathogenic variants reduce ATM function and facilitate the accumulation of somatic changes. The predisposition has incomplete penetrance: inheriting a variant does not imply developing cancer, and the risk depends on the allele, sex, age, and family history. It is best established for female breast cancer, especially estrogen receptor-positive, as well as pancreatic, prostate, and stomach cancer. Associations with ovarian cancer, colon cancer, or melanoma are modest and require confirmation. In population studies, these variants are detected in approximately 0.35% of controls, with differences between ancestral groups.
Symptoms
Heterozygous individuals do not present specific symptoms before developing a tumor. The manifestation depends on the cancer and usually appears in adulthood, although an earlier onset may exist. Breast cancer predominates in women; pancreatic cancer can appear in both sexes, and in men, prostate cancer, sometimes aggressive. The expression is variable and many carriers never develop cancer. Heterozygotes do not present the ataxia, immunodeficiency, or extreme radiosensitivity of biallelic ataxia-telangiectasia.
Disease management
There is no treatment that eliminates predisposition, but surveillance favors early diagnosis. In women, annual breast MRI is usually indicated from 30-35 years of age and mammography from 40, according to local guidelines and individual risk. Prostate and pancreatic screening depends on the country and family history; pancreatic surveillance, when appropriate, is performed using magnetic resonance cholangiopancreatography or endoscopic ultrasound in expert centers. Risk-reducing mastectomy is not routinely recommended. Established cancer is treated according to usual protocols and radiotherapy is not generally contraindicated in heterozygotes. PARP inhibitors, ATR inhibitors, and other targeted therapies are being investigated, but their specific benefit is not defined.
Genes analyzed
Bibliography
Schon KR, Pal T. ATM-Related Cancer Predisposition. GeneReviews®. University of Washington, Seattle. 2026.
Pal T, Schon KR, Astiazaran-Symonds E, et al. Management of individuals with heterozygous germline pathogenic variants in ATM: a clinical practice resource of the American College of Medical Genetics and Genomics. Genet Med. 2025;27(1):101243.
Hall MJ, Bernhisel R, Hughes E, et al. Germline pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Cancer Prev Res. 2021;14(4):433-440.
Hsu FC, Roberts NJ, Childs E, et al. Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene. JAMA Oncol. 2021;7(11):1664-1668.
